CJC-1295 vs ACE-031
Head-to-head comparison of CJC-1295 and ACE-031 for research applications. Both peptides are studied for Body Composition, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Cjc 1295 | Ace 031 |
|---|---|---|
| Category | Growth Hormone Secretagogue | Muscle Growth / Research |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous growth hormone, which in turn increases IGF-1 levels. | ACE-031 is a decoy receptor — it mimics the natural ActRIIB receptor and binds myostatin, activin A/B, GDF-11, and BMP-9/10 before they can engage cell-surface receptors. |
| Evidence Rating | D — Preclinical | C — Early Human or Mixed Evidence |
| Clinical Status | Research-only / Not approved for human use | Phase I/II completed (DMD). Development discontinued by Acceleron Pharma (2013) due to vascular adverse events. Successor programs (ACE-083, local) also discontinued. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | CRITICAL: Vascular safety signals led to clinical discontinuation; Epistaxis (nosebleeds) in multiple subjects |
| Route | Subcutaneous | Subcutaneous injection (DISCONTINUED CLINICAL PROGRAM) |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 0.5-3 mg/kg every 2 weeks (clinical trial doses) |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once every 2 weeks (from clinical trial protocol) |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~90,000 g/mol (Fc-fusion protein) |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~10-14 days (Fc-mediated FcRn recycling) |
Overview
CJC-1295 and ACE-031 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
ACE-031 — Mechanism & Evidence
ACE-031 is a soluble form of the activin type IIB receptor (ActRIIB) fused to a human IgG1 Fc domain (MW ~90,000 g/mol). Acceleron Pharma conducted Phase I and Phase II clinical trials in Duchenne muscular dystrophy (DMD) before discontinuing development due to vascular safety signals (nosebleeds, telangiectasias).
Key claims: Increases lean muscle mass; Potential therapy for muscular dystrophy; Broadly inhibits muscle-wasting pathways.
Shared Research Applications
Both peptides are studied for: Body Composition.
CJC-1295 is also researched for: Anti-Aging.
ACE-031 is also researched for: no additional unique applications.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
ACE-031: CRITICAL: Vascular safety signals led to clinical discontinuation Epistaxis (nosebleeds) in multiple subjects Telangiectasias (dilated blood vessels in skin/mucosa)
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe